Illumina Inc.

Alpha Score of 49 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Illumina, Inc. develops, manufactures, and markets sequencing- and array-based solutions for genetic and genomic analysis worldwide, including in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company provides instruments and consumables such as reagents, flow cells, and library preparation kits, along with whole-genome sequencing kits for genomes of varying size and complexity, and targeted resequencing kits for exomes, specific genes, RNA, and other genomic regions. Its offerings support whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services, serving research, clinical, and applied markets through the Core Illumina segment. These technologies enable large-scale analysis of genetic variation and function, powering advancements in life science research, translational and consumer genomics, and molecular diagnostics. Founded in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers innovative, flexible, and scalable platforms to meet diverse customer needs in genomic solutions.